Current Problems in Cancer
Volume 32, Issue 6 , Pages 242-271 , November 2008

Salvage Therapy for Radiorecurrent Prostate Cancer

  • John F. Ward, MD (Assistant Professor)

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author InformationAddress correspondence to John F. Ward, MD, Department of Urology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA
    • ,
  • Lance C. Pagliaro, MD (Assistant Professor)

      Affiliations

    • Department of Genitourinary Medical Oncology; University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Louis L. Pisters, MD (Professor)

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

References 

  1. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(suppl):IV49–IV54
  2. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57(4):915–928
  3. Kaplan ID, Prestidge BR, Bagshaw MA, Cox RS. The importance of local control in the treatment of prostatic cancer. J Urol. 1992;147(3):917–921
  4. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005;23(32):8198–8203
  5. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43(1):12–27
  6. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? (Results for 498 patients). Int J Radiat Oncol Biol Phys. 2000;48(2):355–367
  7. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45(4):624–631discussion 631-2
  8. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the Cryo On-Line Data Registry. J Urol. 2008;180:559–564
  9. Pisters LL. Comment on: Treatment failure after primary and salvage therapy for prostate cancer. Cancer. 2008;112(2):225–227
  10. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after the primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112:307–314
  11. Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14:99
  12. Gonder MJ, Soanes WA, Smith V. Experimental prostate cryosurgery. Invest Urol. 1964;1:610–619
  13. Lam JS, Pisters LL, Belldegrun ES. Cryotherapy for Prostate Cancer Campbell's Urology Textbook. 9th ed.. The Netherlands: Elsevier Amsterdam; 2007;chapter 101
  14. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37(3):171–186
  15. Cooper IS, Hirose T. Application of cryogenic surgery to resection of parenchymal organs. N Engl J Med. 1966;274(1):15–18
  16. Pisters LL, Von Eschenbach AC, Scott SM, Swanson DA, Dinney CPN, Pettaway CA, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921–926
  17. Rewcastle JC, Sandison GA, Hahn LJ, Saliken JC, McKinnon JG, Donnelly BJ. A model for the time dependent distribution within an iceball surrounding a cryoprobe. Phys Med Biol. 1998;43(12):3519–3534
  18. Rewcastle JC, Sandison GA, Muldrew K, Saliken JC, Donnelly BJ. A model for the time dependent three dimensional distribution within iceballs surrounding multiple cryoprobes. Med Phys. 2001;28(6):1125–3
  19. Sandison GA. Future directions for cryosurgery computer treatment planning. Urology. 2002;60(suppl 1):50–55
  20. Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20(11):2664–2671
  21. Pisters LL, Perrotte P, Scott SM, Greene GF, Von Eschenbach AC. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol. 1999;17(8):2514–2520
  22. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107(2):275–280
  23. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostates cancer (Evidence for tumor progression). Cancer. 1993;71(11):3783–3787
  24. Greene GF, Pisters LL, Scott SM, Von Eschenbach AC. Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol. 1998;160:86–90
  25. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165:1937
  26. Bahn DK, Lee F, Silverman P, Bahn E, Badalament R, Kumar A, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2:111
  27. Han KR, Belldegrun ES. Third generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 2004;93:14
  28. Lam JS, Leppert JT, Koski ME, Vemulapalli SN, Belldegrun ES. Salvage cryosurgical ablation for radio-recurrent prostate cancer using third generation cryoneedles: the University of California-Los Angeles Experience. J Urol. 2005;173:181;abstract 665
  29. Katz AE, Prepelica KL, Masson P, Benson MC, McKiernan JM. Salvage cryosurgical ablation of the prostate (TCAP) for patients failing radiation: 10-year experience. J Urol. 2005;173:450;abstract 1662
  30. Donnelly BJ, Saliken JC, Ernst DS, Weber B, Robinson JW, Brasher PM, et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis. 2005;8:235
  31. Izawa JI, Perrotte P, Greene GF, Scott SM, Levy L, McGuire E, et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol. 2001;165:867–870
  32. Huang WC, Kuroiwa K, Serio AM, Bianco FJ, Fine SW, Shayegan B, et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol Apr. 2007;177(4):1324–1329quiz 1591
  33. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005;173(4):1156–1160
  34. Bianco FJ, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(2):448–453
  35. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Am Med Assoc. 2004;291(11):1325–1332
  36. Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol. 2005;23(32):8198–8203
  37. Leibovici D, Spiess PE, Heller L, Rodriguez-Bigas M, Chang G, Pisters LL. Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade. Urol Oncol. 2008;26(1):9–16
  38. Vallancien G, Gupta R, Cathelineau X, Baumert H, Rozet F. Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol. 2003;170(5):1838–1840
  39. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, et al. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005;174(6):2186–2190
  40. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, et al. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005;103(10):2060–2066
  41. Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132(9):743–756
  42. Pisters LL. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol. 2000;163(6):1771–1774
  43. Ahlering TE, Lieskovsky G, Skinner DG. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol. 1992;147(3):900–902
  44. Rogers E. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995;153(1):104–110
  45. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol. 2005;173(3):781–783
  46. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, et al. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate. 2005;62(1):101–104
  47. Bochner BH, Figueroa AJ, Skinner EC, Lieskovsky G, Petrovich Z, Boyd SD, et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol. 1998;160(1):29–33
  48. Hilsabeck JR. The presacral space as a collector of fluid accumulations following rectal anastomosis: tolerance of rectal anastomosis to closed suction pelvic drainage. Dis Colon Rectum. 1982;25(7):680–684
  49. Abdulatif M, El-Sanabary M. Caudal neostigmine, bupivacaine, and their combination for postoperative pain management after hypospadias surgery in children. Anesth Analg. 2002;95(5):1215–1218
  50. Radice E, Nelson H, Mercill S, Farouk R, Petty P, Gunderson L. Primary myocutaneous flap closure following resection of locally advanced pelvic malignancies. Br J Surg. 1999;86(3):349–354
  51. Pendleton J, Pisters LL, Nakamura K, Anai S, Rosser CJ. Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going?. Urol Oncol. 2007;25(1):11–18
  52. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer (The Lupron Depot Neoadjuvant Prostate Cancer Study Group). J Urol. 1995;154(2):424–428
  53. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med. 1993;16(6):499–509
  54. Schulman CC, Debruyne EM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. Four-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer (European Study Group on Neoadjuvant Treatment of Prostate Cancer). Eur Urol. 2000;38(6):706–713
  55. Aus G, Abrahmsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90(6):561–566
  56. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520
  57. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512
  58. Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780
  59. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142
  60. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240
  61. Eastham JA, Kelly WK, Grossfeld GD, Small EJ Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(suppl 1):55–62
  62. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22(11):2108–2121
  63. Tolcher AW. Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor. J Urol. 2004;171(2):S41–S43discussion S44
  64. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006;5(2):144–149
  65. Pantuck AJ, Zomorodian N, Belldegrun AS. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007;8(1):3–4
  66. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999;10(7):1239–1249
  67. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, et al. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis. 1999;2(S3):S27
  68. ClinicalTrials.gov. U.S. National Institutes of Health. Available from: http://www.clinicaltrials.gov.
  69. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007;13(4):1224–1231
  70. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004;10(8):2587–2593

PII: S0147-0272(08)00056-1

doi: 10.1016/j.currproblcancer.2008.10.001

Current Problems in Cancer
Volume 32, Issue 6 , Pages 242-271 , November 2008

Article Tools

* Image Usage & Resolution